BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 54 found
  Current Search:  rebif: 54     

HTML
100%
UPDATE 1-Merck KGaA open to taking part in ImClone bid
FRANKFURT, Sept 30 (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.

drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.

'We are not the white...

Forbes.com:  Sep 30 2008 2:25PM
Matching: rebif
Find similar documents
HTML
100%
UPDATE 1-Merck KGaA open to taking part in ImClone bid
FRANKFURT, Sept 30 (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.

drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.

'We are not the white...

Interactive Investor International:  Sep 30 2008 1:16PM
Matching: rebif
Find similar documents
HTML
100%
Merck KGaA open to taking part in ImClone bid
FRANKFURT (Reuters) - Merck KGaA would not bid for ImClone Systems Inc on its own, but may consider taking part in a potential approach for the U.S.

drugmaker, Merck's Chief Executive Karl-Ludwig Kley said.

'We are not the white knight ....

Reuters via MSN Money:  Sep 30 2008 1:13PM
Matching: rebif
Find similar documents
HTML
100%
Merck's Phase IIIb multiple sclerosis study meets endpoint
The primary objective of the Improve study was to evaluate the efficacy of the new formulation of Rebif, compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic...
Pharmaceutical Business Review:  Sep 25 2008 7:37AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of TreatmentData Presented at Late-Breaking Session of the World Congress on Treatment and...
Healthcare Sales & Marketing Network:  Sep 23 2008 11:32PM
Matching: rebif
Find similar documents
HTML
100%
Merck KGaA Rebif trial meets endpoint
_ Merck KGaA Rebif trial meets endpoint.
Marketletter Publications:  Sep 24 2008 12:44AM
Matching: rebif
Find similar documents
HTML
100%
Merck's IMPROVE study meets primary endpoints
Merck KGaA and its division Merck Serono announced that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.

The primary objective of the study was to evaluate the...

PharmaBiz:  Sep 23 2008 10:57AM
Matching: rebif
Find similar documents
HTML
100%
Primary Endpoint Met in Merck Serono’s MS Trial
Merck Serono received promising findings from its Phase IIIb study using a new formulation of Rebif in patients with relapsing-remitting multiple sclerosis (MS).

The two-arm, randomized, double-blind, controlled, multicenter,...

FDA News:  Sep 23 2008 9:44PM
Matching: rebif
Find similar documents
HTML
100%
Results from IMPROVE study show therapeutic effect of new formulation of Rebif(R) at 16 weeks in patients with
Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment Data Presented at Late-Breaking Session of the World Congress on Treatment and...
Checkbiotech:  Sep 23 2008 6:16PM
Matching: rebif
Find similar documents
HTML
100%
Merck KGaA: Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif at 16 Weeks in Pati
Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif on disease activity as measured by MRI after 16 weeks of treatment Data presented at late breaking session of the World Congress on Treatment...
Pharma Live:  Sep 22 2008 3:11PM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada GENEVA,...
PR Newswire via Yahoo!:  Sep 22 2008 6:09AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
GENEVA, Switzerland, September 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary...
Yahoo! Canada:  Sep 22 2008 6:07AM
Matching: rebif
Find similar documents
HTML
100%
Merck says results of Rebif encouraging
Singapore, Sept 22, 2008: Germanys Merck and its division Merck Serono say the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint.

A company release said the primary...

Bio Spectrum Asia:  Sep 22 2008 7:14AM
Matching: rebif
Find similar documents
HTML
100%
Merck KGaA: Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif at 16 Weeks in Pati
Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif on disease activity as measured by MRI after 16 weeks of treatment Data presented at late breaking session of the World Congress on Treatment...
Therapeutics Daily:  Sep 22 2008 1:07PM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
-- Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif(R) on disease activity as measured by MRI after 16 weeks of treatment -- Data presented at late-breaking session of the World Congress on...
PR Newswire:  Sep 22 2008 7:03AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
- Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment...
FinanzNachrichten.de:  Sep 22 2008 6:29AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New
GENEVA, Switzerland, September 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary...
PR Newswire via MSN Money:  Sep 22 2008 6:14AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With
GENEVA, Switzerland, September 22 /PRNewswire/ -- - Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late...
Calibre Macro World:  Sep 22 2008 6:10AM
Matching: rebif
Find similar documents
HTML
100%
Results From IMPROVE Study Show Therapeutic Effect of New Formulation
- Study Meets Primary Endpoint by Demonstrating Significant Effect of new Formulation of Rebif(R) on Disease Activity as Measured by MRI After 16 Weeks of Treatment - Data Presented at Late-Breaking Session of the World Congress on Treatment...
FinanzNachrichten.de:  Sep 22 2008 6:10AM
Matching: rebif
Find similar documents
HTML
100%
BRIEF-Merck says results from study show therapeutic effect
FRANKFURT, Sept 22 (Reuters) - Merck KGaA: * Says results from improve study show therapeutic effect of new formulation of rebif at 16 weeks in patients with multiple sclerosis ((Frankfurt Newsroom; +49 69 7565 1272)) tf.TFN-Europe...
Forbes.com:  Sep 22 2008 7:59AM
Matching: rebif
Find similar documents
HTML
100%
Bayer says early Betaferon use most effective
FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.

Compared to initial...

Times Colonist:  Sep 21 2008 8:48AM
Matching: rebif
Find similar documents
HTML
100%
Bayer says early Betaferon use most effective
FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.

Compared to initial...

Vancouver Sun:  Sep 21 2008 4:23AM
Matching: rebif
Find similar documents
HTML
100%
Bayer says early Betaferon use most effective
FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker said on Saturday.

Compared to initial...

The Province:  Sep 21 2008 3:47AM
Matching: rebif
Find similar documents
HTML
100%
Merck Serono initiates Phase III multiple sclerosis trial
The trial, called Oracle MS will evaluate the safety and efficacy of two dosage regimens of cladribine tablets versus placebo in the treatment of patients who have experienced a first clinical event suggestive of multiple sclerosis (MS).
Pharmaceutical Business Review:  Sep 20 2008 11:54AM
Matching: rebif
Find similar documents
HTML
100%
Merck KGaA Completes Enrollment in the REFLEX Trial of Rebif in Patients at Risk of Developing Multiple Sclero
Merck KGaA announced today that its Merck Serono division has completed patient enrollment in the REFLEX trial (REbif FLEXible dosing in early multiple sclerosis).

This randomized, double-blind, placebo-controlled, international...

Pharma Live:  Sep 19 2008 2:34PM
Matching: rebif
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.